Scott Schoenhaus
Stock Analyst at Keybanc
(1.85)
# 2,627
Out of 4,479 analysts
69
Total ratings
33.33%
Success rate
-9.49%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HQY HealthEquity | Maintains: Overweight | $95 → $100 | $85.76 | +16.60% | 3 | Jun 5, 2024 | |
| LFMD LifeMD | Initiates: Overweight | $12 | $6.62 | +81.27% | 1 | Jun 5, 2024 | |
| PGNY Progyny | Downgrades: Sector Weight | n/a | $28.33 | - | 5 | May 10, 2024 | |
| ALIT Alight | Maintains: Overweight | $12 → $11 | $7.09 | +55.15% | 4 | May 9, 2024 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $8 → $7 | $2.77 | +152.71% | 2 | May 8, 2024 | |
| RCM R1 RCM | Downgrades: Sector Weight | n/a | $10.90 | - | 8 | Apr 10, 2024 | |
| HCAT Health Catalyst | Downgrades: Sector Weight | n/a | $6.10 | - | 4 | Apr 10, 2024 | |
| GDRX GoodRx Holdings | Upgrades: Overweight | $9 | $7.82 | +15.09% | 4 | Apr 10, 2024 | |
| CERT Certara | Upgrades: Overweight | $23 | $13.66 | +68.37% | 2 | Apr 10, 2024 | |
| VEEV Veeva Systems | Maintains: Overweight | $232 → $250 | $182.85 | +36.72% | 10 | Mar 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $15 → $16 | $7.16 | +123.46% | 4 | Mar 4, 2024 | |
| ABSI Absci | Maintains: Overweight | $5 → $8 | $2.97 | +169.36% | 3 | Mar 4, 2024 | |
| SDGR Schrödinger | Maintains: Overweight | $38 → $33 | $20.33 | +62.32% | 2 | Feb 29, 2024 | |
| PHR Phreesia | Maintains: Overweight | $40 → $30 | $20.50 | +46.34% | 4 | Dec 7, 2023 | |
| OMCL Omnicell | Downgrades: Sector Weight | n/a | $26.16 | - | 8 | Oct 11, 2023 | |
| ODD Oddity Tech | Initiates: Overweight | n/a | $40.92 | - | 1 | Aug 15, 2023 | |
| MDRX Veradigm | Initiates: Sector Weight | n/a | $9.66 | - | 1 | Sep 16, 2022 | |
| TDOC Teladoc Health | Initiates: Sector Weight | n/a | $9.40 | - | 2 | Sep 16, 2022 | |
| IQV IQVIA Holdings | Upgrades: Overweight | n/a | $207.47 | - | 1 | Apr 16, 2021 |
HealthEquity
Jun 5, 2024
Maintains: Overweight
Price Target: $95 → $100
Current: $85.76
Upside: +16.60%
LifeMD
Jun 5, 2024
Initiates: Overweight
Price Target: $12
Current: $6.62
Upside: +81.27%
Progyny
May 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $28.33
Upside: -
Alight
May 9, 2024
Maintains: Overweight
Price Target: $12 → $11
Current: $7.09
Upside: +55.15%
AbCellera Biologics
May 8, 2024
Maintains: Overweight
Price Target: $8 → $7
Current: $2.77
Upside: +152.71%
R1 RCM
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $10.90
Upside: -
Health Catalyst
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $6.10
Upside: -
GoodRx Holdings
Apr 10, 2024
Upgrades: Overweight
Price Target: $9
Current: $7.82
Upside: +15.09%
Certara
Apr 10, 2024
Upgrades: Overweight
Price Target: $23
Current: $13.66
Upside: +68.37%
Veeva Systems
Mar 5, 2024
Maintains: Overweight
Price Target: $232 → $250
Current: $182.85
Upside: +36.72%
Recursion Pharmaceuticals
Mar 4, 2024
Maintains: Overweight
Price Target: $15 → $16
Current: $7.16
Upside: +123.46%
Absci
Mar 4, 2024
Maintains: Overweight
Price Target: $5 → $8
Current: $2.97
Upside: +169.36%
Schrödinger
Feb 29, 2024
Maintains: Overweight
Price Target: $38 → $33
Current: $20.33
Upside: +62.32%
Phreesia
Dec 7, 2023
Maintains: Overweight
Price Target: $40 → $30
Current: $20.50
Upside: +46.34%
Omnicell
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $26.16
Upside: -
Oddity Tech
Aug 15, 2023
Initiates: Overweight
Price Target: n/a
Current: $40.92
Upside: -
Veradigm
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $9.66
Upside: -
Teladoc Health
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $9.40
Upside: -
IQVIA Holdings
Apr 16, 2021
Upgrades: Overweight
Price Target: n/a
Current: $207.47
Upside: -